Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Xetra  >  Merck KGaA    MRK   DE0006599905

MERCK KGAA

(MRK)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Merck : says it has overcome production shortages in vaccine materials

share with twitter share with LinkedIn share with facebook
09/16/2020 | 01:50pm EDT

* CEO cites shortages in filtration products

* Also had to clear backlog in bioreactors, diagnostic chems

* Life Science unit has invested more than 425 mln eur since 2017

FRANKFURT, Sept 16 (Reuters) - Germany's Merck KGaA , one of the world's largest suppliers of materials and equipment for the production of biotech drugs, is boosting output capacity to keep up with a surge in demand from companies fighting the COVID-19 pandemic.

Diversified Merck makes chemicals for the electronic industry as well as speciality drugs, while its Life Science division supplies lab equipment and plays a role in more than 50 global projects aiming to develop a vaccine against COVID-19.

"We are a very important partner for diagnostic firms, vaccine companies and companies that want to manufacture antibodies," Merck Chief Executive Stefan Oschmann told Reuters, referring to a new class of potential treatments for people infected with the new coronavirus.

Merck's Life Science division, as well as its competitors, have been expanding to meet the increase in demand and to support the global effort to mass-produce vaccines, he said.

Competitors of the business include Thermo Fisher and Sartorius. The COVID-19 pandemic, which has claimed more than 900,000 lives globally, has triggered a race to develop an effective vaccine with 35 projects already testing their candidates on humans.

Areas hampered by temporary shortages included filtration products, where Merck has rushed to clear order backlogs, said Oschmann.

Single-use plastic bioreactors, which are replacing traditional metal tanks for the fermentation of therapeutic proteins, were also temporarily out of stock in some places, requiring teams "to work day and night, so far quite successfully", he added.

The company has also overcome shortages in its supply of speciality chemicals that help extract viral material from samples for the diagnostics industry.

The Life Science unit has invested more than 425 million euros ($503 million) to meet growing market demand since 2017, but the CEO declined to give detailed figures for this year.

The company said earlier on Wednesday at its capital markets day that it now expected 6-9% revenue growth at Life Science over the next five years, versus 5-8% previously.

($1 = 0.8448 euros) (Reporting by Ludwig Burger; Editing by Michelle Adair and Mark Potter)


Stocks mentioned in the article
ChangeLast1st jan.
MERCK KGAA -4.04% 127.15 Delayed Quote.20.69%
SARTORIUS AG -1.81% 325 Delayed Quote.85.71%
share with twitter share with LinkedIn share with facebook
All news about MERCK KGAA
10/30MERCK KGAA : Sell rating from Goldman Sachs
MD
10/29MERCK : Mammoth Biosciences Partner to Produce, Scale Up Covid-19 Test
DJ
10/28MERCK KGAA : Kepler Cheuvreux remains its Buy rating
MD
10/28MERCK : to Invest EUR20 Million in Display-Technology Production
DJ
10/27MERCK : MAVENCLAD® (cladribine tablets) is available through public drug plans f..
AQ
10/27MERCK KGAA : JP Morgan remains Neutral
MD
10/21MERCK KGAA : Morgan Stanley reaffirms its Neutral rating
MD
10/21MERCK KGAA : Bernstein reiterates its Neutral rating
MD
10/16Physiomics Wins Contracts With Existing Customers
DJ
10/15MERCK : Global Head of R&D for Healthcare to Retire
DJ
More news
Financials
Sales 2020 17 300 M 20 146 M 20 146 M
Net income 2020 1 724 M 2 008 M 2 008 M
Net Debt 2020 10 781 M 12 554 M 12 554 M
P/E ratio 2020 30,5x
Yield 2020 1,07%
Capitalization 55 282 M 64 424 M 64 376 M
EV / Sales 2020 3,82x
EV / Sales 2021 3,53x
Nbr of Employees 57 523
Free-Float 29,7%
Chart MERCK KGAA
Duration : Period :
Merck KGaA Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MERCK KGAA
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 22
Average target price 126,95 €
Last Close Price 127,15 €
Spread / Highest target 18,0%
Spread / Average Target -0,15%
Spread / Lowest Target -20,6%
EPS Revisions
Managers
NameTitle
Stefan Oschmann Chairman-Executive Board & CEO
Wolfgang Heinz Büchele Chairman-Supervisory Board
Marcus Kuhnert Chief Financial Officer
Christian Raabe Independent Member-Supervisory Board
Edeltraud Glänzer Independent Member-Supervisory Board
Sector and Competitors
1st jan.Capitalization (M$)
MERCK KGAA20.69%64 424
ZHANGZHOU PIENTZEHUANG PHARMACEUTICAL., LTD108.70%20 679
KYOWA KIRIN CO., LTD.0.66%13 303
BETTA PHARMACEUTICALS CO., LTD.62.97%6 450
YUHAN CORPORATION25.79%3 282
RECIPHARM AB (PUBL)9.32%1 627